Abstract：Objective To observe the clinical effect and adverse reactions of Sacubitril Valsartan Sodium in the treatment of patients with maintenance hemodialysis (MHD) combined with heart failure.Methods A total of 44 patients with MHD and heart failure who hospitalized in the Department of Nephrotic Rheumatism of the Central Hospital of Qianjiang from October 2017 to June 2019 were selected as the research subjects.They were divided into observation group and control group according to the random number table method,with 22 patients in each group.All patients received MHD and symptomatic support therapy,the observation group was treated with Sacubitril Valsartan Sodium on this basis.The total effective rate and the total incidence of adverse reactions during the treatment of two groups were compared,at the same time,the cardiac function indexes such as left ventricular end systolic diameter (LVESD),left ventricular end diastolic diameter (LVEDD),stroke volume (SV),left ventricular ejection fraction (LVEF) and the expression levels of serum N-terminal pro-B-type natriuretic peptide (NT-proBNP),angiotensin Ⅱ(Ang Ⅱ),aldosterone(ALD) in the two groups before and after treatment were detected.Results The total effective rate of observation group was higher than that of control group,and the difference was statistically significant (P＜0.05).There were no significant differences in cardiac function indexes between two groups before treatment (P＞0.05).After treatment,the LVEF and SV of two groups were higher than those of before treatment,the LVESD and LVEDD of two groups were lower than those before treatment,the LVEF and SV in observation group were higher than those of control group,and the LVESD and LVEDD in observation group were lower than those of control group,the differences were statistically significant(P＜0.05).There were no significant differences in the expression levels of cytokines between the two groups before treatment (P＞0.05).After treatment,the expression levels of cytokines such as NT-proBNP,Ang Ⅱ,ALD were lower than those of before treatment,and the indexes of observation group were lower than those of the control group,the differences were statistically significant (P＜0.05).There was no significant difference in the total incidence of adverse reactions between the two groups (P＞0.05).Conclusion The efficacy of Sacubitril Valsartan Sodium in the treatment of MHD patients with heart failure is significant,which can not only effectively inhibit ventricular remodeling,but also significantly improve the neuroendocrine status,and has a high safety and reliability.
文静； 刘妍. 沙库巴曲缬沙坦钠治疗维持性血液透析合并心力衰竭患者的效果[J]. 中国当代医药, 2022, 29(22): 10-13转17.
WEN Jing LIU Yan. Effect of Sacubitril Valsartan Sodium in the treatment of patients with maintenance hemodialysis combined with heart failure. 中国当代医药, 2022, 29(22): 10-13转17.
Beusekamp JC，Tromp J，vander Wal HH，et al.Potassium and the use of renin-angiotensin-aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTAT-CHF[J].Eur J Heart Fail，2018，20（5）：923-930.
[9]
Correction to：2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure：A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America[J].Circulation，2016，134（13）：e298-293.
[10]
Wang TD，Tan RS，Lee HY，et al.Effects of Sacubitril/Valsartan （LCZ696） on Natriuresis，Diuresis，Blood Pressures，and NT-proBNP in Salt-Sensitive Hypertension[J].Hypertension，2017，69（1）：32-41.
[11]
Albert NM，Swindle JP，Buysman EK，et al.Lower hospitalization and healthcare costs with sacubitril/valsartan versus Angiotensin-Converting enzyme inhibitor or Angiotensin-Receptor blocker in a retrospective analysis of patients with heart failure[J].J Am Heart Assoc，2019，8（9）：11089.
[12]
Cunningham JW，Claggett BL，O′Meara E，et al.Effect of Sacubitril/Valsartan on biomarkers of extracellular matrix regulation in patients with HFpEF[J].J Am Coll Cardiol，2020，76（5）：503-514.
[13]
Myhre PL，Vaduganathan M，Claggett B，et al.B-type natriuretic peptide during treatment with Sacubitril/Valsartan：the PARADIGM-HF trial[J].J Am Coll Cardiol，2019，73（11）：1264-1272.
京公网安备 11010502046607号